BrightSpring Health Services, Inc. Common Stock Q1 FY2026 earnings call

• Bright Spring is a national leader in home and community health services, focusing on quality care. Pharmacy solutions have healthy growth with specialty and infusion showing script growth. Home and Community Pharmacy aims for organic growth. Provider side home healthcare expects organic growth from market share gains. Integrating Acquired and Medicis and LHC branches with EBITDA contribution. Palliative and Hospice well-positioned. Rehab has consistent growth. Home-based primary care and value-based care initiatives show potential. First quarter financial results were strong with revenue growth, adjusted EBITDA increase, and margin expansion from mix and operational efficiencies. Quality measures in various segments were high.

Total company revenue was $3.6 billion, growing 26% year over year. Pharmacy Solutions revenue was $3.2 billion, growing 25%, with specialty and infusion revenue $2.6 billion (36% growth) and home and community pharmacy revenue $527 million (9% decline). Provider services revenue was $442 million, growing 28%. Pharmacy Solutions gross profit was $301 million (48% growth), adjusted EBITDA $169 million (46% increase). Provider services gross profit was $181 million (35% growth), adjusted EBITDA $66 million (29% growth).

Total revenue expected to be in range of $14.725 billion to $15.225 billion, including pharmacy solutions $12.85 billion to $13.3 billion and provider services $1.875 billion to $1.925 billion. Total adjusted EBITDA expected in range of $795 million to $825 million, reflecting 28.7% to 33.6% growth over 2025, including ~$30 million contribution from acquired assets.

Q: Talk about growth initiatives hitting P&L, especially infusion.

A: Broad-based growth, double-digit growth in acute and chronic specialty infusion, launched concierge program for IVIG.

Q: Interest in large M&A and leverage comfort?

A: Disciplined approach, target leverage mid twos.

Q: Medicare environment impact?

A: Consistent, working on value-based care, applying to ACO program.

Q: Revenue headwind tracking?

A: Tracking towards expected numbers.

Q: Specialty script growth and home and community rev growth ex genesis?

A: Specialty and infusion script growth ~30%, home and community X uneconomic customers mid-single digits growth.

Q: Exposure to PBM biosimilar dynamics?

A: Little exposure, focus on oral solids.

Q: Infusion LDD updates?

A: Won five LDDs, launching concierge programs.

Q: GP per script drivers?

A: Specialty infusion growth, brand to generic mix shift, purchasing leverage, fee-for-service.

Q: Margin outlook?

A: Slight margin expansion expected, consistent with Q1.

Q: Operational efficiencies and AI applications?

A: Working on automation tools, order intake projects, portal connections, centralizing order intake, over 20 people on AI team.

Q: Biosimilar opportunity?

A: Potential opportunity, no near-term risks.

Q: Operational initiatives contribution to margin?

A: Consistent program, over 700 projects with nine figures savings.

Q: Fee-for-service business scale?

A: Growing in 40-50% range, meaningful part of business.

Q: Market share of specialty business?

A: Share increasing with LDDs.

Q: Corporate costs plan?

A: Small pickup expected.

Q: Generic conversion landscape?

A: Consistent strategy, multifaceted execution.

Q: Defensiveness against PBM moves?

A: Partnering, focusing on quality and scale.

Q: Pharmacy solutions guidance difference?

A: Related to year over year growth and sequential growth balance.

Q: SG&A increase in quarter?

A: Investments in IT, sales force, etc.

Q: PBM private label dynamic?

A: Little exposure, no big changes in agreements.